Table 1.
Patient characteristics.
Table 2.
Comparison of pathologic response assessment systems after neoadjuvant chemotherapy for different subtypes of breast cancer.
RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio.
Table 3.
Kappa values for the different pathologic response assessment systems after systemic neoadjuvant therapy.
RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio.
Fig 1.
Kaplan—Meier survival curves for ypTNM stage, RCB, RDBN, TRR, Sataloff's T classification, and Miller-Payne grade showing disease-free survival rates for patients with HR+/HER2- breast cancer treated with anthracycline with/without taxane-based neoadjuvant chemotherapy.
Three evaluation systems assessing the absolute residual tumor, ypTNM stage, RCB, and RDBN, have prognostic significance. (RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio).
Fig 2.
Kaplan-Meier survival curves for ypTNM stage, RCB, RDBN, TRR, Sataloff's T classification, and Miller-Payne grade showing disease-free survival rates for patients with HR+/HER2+ breast cancer treated with anthracycline with/without taxane-based neoadjuvant chemotherapy.
None of the evaluation systems yield distinct Kaplan-Meier survival curves, while RDBN, Sataloff's T classification, and Miller-Payne grade show statistical significance (p<0.05). (RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio).
Fig 3.
Kaplan-Meier survival curves for ypTNM stage, RCB, RDBN, TRR, Sataloff's T classification, and Miller-Payne grade showing disease-free survival rates for patients with HR-/HER2+ breast cancer treated with anthracycline with/without taxane-based neoadjuvant chemotherapy.
None of the evaluation systems yield distinct Kaplan-Meier survival curves, while TRR and Miller-Payne grade show statistical significance (p<0.05). (RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio).
Fig 4.
Kaplan-Meier survival curves for ypTNM stage, RCB, RDBN, TRR, Sataloff's T classification, and Miller-Payne grade showing disease-free survival rates for patients with triple negative breast cancer treated with anthracycline with/without taxane-based neoadjuvant chemotherapy.
All the pathologic response evaluation systems yield distinct Kaplan-Meier survival curves and have prognostic significance. (RCB, residual cancer burden; RDBN, residual disease in breast and node; TRR, tumor response ratio).
Fig 5.
Time-dependent ROC curve estimation analysis for ypTNM stage, RCB, RDBN, TRR, Sataloff's T classification, and Miller-Payne grade in specific subtypes of breast cancer treated with anthracycline with/without taxane-based neoadjuvant chemotherapy.
(A) HR+/HER2-. The ranking of predictive accuracy are variably changed through time, while AUC values of all evaluation systems are over 0.5. (B) HR+/HER2+. The rankings of predictive accuracy are variably changed through time, while AUC values of all evaluation systems are over 0.5. (C) HR-/HER2+. The rankings of predictive accuracy are variably changed through time, while AUC values of all evaluation systems are over 0.5. (D) triple-negative tumors. The values of AUC of all evaluation systems are over 0.5 and relatively constant over time (Line color: black, ypTNM stage; red, RCB; green, RDBN; yellow, TRR; blue, Sataloff’s T; sky-blue, Sataloff’s N; pink, Miller Payne grade) (AUC, area under the curve).